Comment on CMS-2026-1255-0001
NASPGHAN, ASGESupportAdvocacy
Summary: A coalition of medical societies representing digestive disease patients and physicians supports the proposed rule to expand interoperability and transparency for drug prior authorizations. They advocate for stricter federal safeguards against "step therapy," including standardized exception processes, mandatory continuity of care across payers, and the prohibition of "non-medical switching."
The following societies representing digestive disease patients and physicians offer the attached comments regarding the prior authorization provisions of the proposed rule, as well as offer a response to the RFI on step therapy: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Crohn’s & Colitis Foundation, Digestive Health Physicians Association, and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition